Basmisanil

Basmisanil
Clinical data
Other names	RG-1662; RO5186582
ATC code	None;
Identifiers
	IUPAC name (1,1-Dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone;
CAS Number	1159600-41-5;
PubChem CID	57336276;
ChemSpider	34500832;
UNII	788PET5SUA;
KEGG	D10863 ;
CompTox Dashboard (EPA)	DTXSID201032402 ;
Chemical and physical data
Formula	C21H20FN3O5S
Molar mass	445.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4;
	InChI InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3; Key:VCGRFBXVSFAGGA-UHFFFAOYSA-N;

Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α₅ subunit-containing GABA_A receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.^[1]^[2]^[3] As of June 2016, it is no longer studied for this purpose.^[4] It underwent a clinical trial for cognitive impairment in patients with schizophrenia.^[5]

References

^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". Journal of Alzheimer's Disease. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
^ Hurley D (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
^ Jensen HS, Nichol K, Lee D, Ebert B (2014). "Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes". PLOS ONE. 9 (2): e88456. Bibcode:2014PLoSO...988456J. doi:10.1371/journal.pone.0088456. PMC 3922815. PMID 24533090.
^ Chevrette M. "Response to the Roche Clinical Trial for CLEMATIS". Retrieved 2016-06-28.
^ Clinical trial number NCT02953639 for "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics" at ClinicalTrials.gov

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.